SCHEMBL25612486

SCHEMBL25612486

OCc1cc(F)cc(SCc2ccccc2)c1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.42
APOBEC3G Q9HC16 1/20 0.38
PTPRC P08575 1/20 0.38
SMN1; SMN2 Q16637 4/20 0.37
ALDH1A1 P00352 3/20 0.37
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
CA2 P00918 3/20 0.37
CA4 P22748 2/20 0.37
CA12 O43570 2/20 0.37
CA1 P00915 2/20 0.37
CA7 P43166 2/20 0.37
CA13 Q8N1Q1 2/20 0.37
LMNA P02545 1/20 0.36
MAPK1 P28482 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25612489 0.85 POLB (0.40) POLBAPOBEC3GPTPRCSMN1; SMN2ALDH1A1
SCHEMBL25612488 0.85 POLB (0.40) POLBAPOBEC3GPTPRCSMN1; SMN2ALDH1A1
SCHEMBL25612487 0.85 POLB (0.40) POLBAPOBEC3GPTPRCSMN1; SMN2ALDH1A1
SCHEMBL25612572 0.78 ALDH1A1 (0.48) POLBPTPRCSMN1; SMN2ALDH1A1KMT2A
SCHEMBL1903485 0.76 APOBEC3G (0.59) POLBAPOBEC3GPTPRCSMN1; SMN2ALDH1A1
SCHEMBL13647657 0.72 DAO (0.47) POLBPTPRCSMN1; SMN2ALDH1A1KMT2A
SCHEMBL25612342 0.72 L3MBTL1 (0.51) POLBPTPRCSMN1; SMN2ALDH1A1KMT2A
SCHEMBL22531477 0.71 TSHR (0.42) POLBSMN1; SMN2ALDH1A1CA2CA12
SCHEMBL31322752 0.71 CYP4F2 (0.33) LMNA
SCHEMBL31645023 0.70 POLB (0.43) POLBAPOBEC3GPTPRCSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382915-A1 GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-11-30 US disclosed
US-20230382915-A1 GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-11-30 US disclosed
WO-2023102228-A1 HETEROCYCLIC COMPOPUNDS AS GCN2 AND PERK KINASE INHIBITORS DECIPHERA PHARMACEUTICALS, LLC (US) 2023-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382915-A1 GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF EIF2AK4, GCN1, EEF2K POLB 1447/4885APOBEC3G 4476/4885PTPRC 2115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.